Redwood Pharma: Accelerated Development of RP501 for Dry Eyes - Analysguiden

In October, Redwood Pharma announced a strategic change in the form of accelerated development of RP501 for dry eyes. RP501 can reach the market within two years and thus generate revenue in the near future. Analysguiden adjusts its target price to SEK 10.

Länk till analysen i sin helhet: https://www.aktiespararna.se/analysguiden/nyheter/analysis-redwood-pharma-accelerated-development-rp501-dry-eyes